Research Article
IL-17 Genetic and Immunophenotypic Evaluation in Chronic Graft-versus-Host Disease
Table 1
Clinical characteristics of allo-HSCT patients and donors (
).
| | Parameters | Total () |
| | Recipient median age in years (range) | 31.5 (5–56) | | Female gender | 25 (43.2%) | | Primary disease | | | (i) Malignant | | | (ii) Chronic myeloid leukemia | 9 (15.5%) | | (iii) Acute myeloid leukemia | 15 (26%) | | (iv) Acute lymphoid leukemia | 5 (8.6%) | | (v) Non-Hodgkin’s lymphoma | 4 (6.9%) | | (vi) Hodgkin’s lymphoma | 3 (5.1%) | | (vii) Other malignancies* | 4 (6.9%) | | (viii) Bone marrow failure syndrome** | 18 (31%) | | HLA match | | | (i) HLA matched related | 52 (89.6%) | | (ii) HLA matched unrelated | 4 (6.8%) | | (iii) HLA mismatched related | 2 (3.6%) | | Donor median age in years (range) | 35.4 (6–69) | | Donor female gender | 21 (36.3%) | | Conditioning regimen | | | (i) BU/CY | 20 (34.5%) | | (ii) CY +/− ATG or Alemtuzumab | 14 (24.2%) | | (iii) BU + FLU +/− Alemtuzumab | 9 (15.5%) | | (iv) CY + FLU +/− Alemtuzumab | 8 (13.8%) | | (v) MEL + FLU +/− Campath | 5 (8.6%) | | (vi) Others*** | 2 (3.4%) | | Ethnic group | Brazilian mixed population | | Source of stem | | | (i) Bone marrow | 32 (55.2%) | | (ii) Peripheral blood stem cells | 25 (43.1%) | | (iii) Umbilical cord blood | 1 (1.7%) |
|
|
Myelodysplastic syndrome (), myelofibrosis (), and multiple myeloma ().
**Paroxysmal nocturnal hemoglobinuria (), severe aplastic anemia (), and Fanconi anemia ().
***BU/MEL () Cytarabine/Campath/FLUD ().
BU: busulfan; CY: cyclophosphamide; FLUD: fludarabine; MEL: melphalan; ATG: antithymoglobulins.
|
